PE20220515A1 - Nuevos compuestos heterociclicos - Google Patents

Nuevos compuestos heterociclicos

Info

Publication number
PE20220515A1
PE20220515A1 PE2021002265A PE2021002265A PE20220515A1 PE 20220515 A1 PE20220515 A1 PE 20220515A1 PE 2021002265 A PE2021002265 A PE 2021002265A PE 2021002265 A PE2021002265 A PE 2021002265A PE 20220515 A1 PE20220515 A1 PE 20220515A1
Authority
PE
Peru
Prior art keywords
oxazin
methanone
chloro
phenyl
disease
Prior art date
Application number
PE2021002265A
Other languages
English (en)
Inventor
Carsten Kroll
Flore Reggiani
Miroslav Kosar
Maurice Biedermann
Bernd Kuhn
Benoit Hornsperger
Uwe Grether
Fionn O`Hara
Hans Richter
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of PE20220515A1 publication Critical patent/PE20220515A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Esta referido a un compuesto heterociclico de formula I, en donde: R1 es arilo, heteroarilo; R2 es H, alquilo; X es -CH2CR3 R4 - o -CH=CR3 -; Y es -O-, -S-, -SO- o -SO2. Entre los compuestos preferidos tenemos los siguientes: [(3R,9aS)-3-(3,4-difluorofenil)-3-hidroxi-1,4,6,7,9,9a-hexahidropirazino[2,1- c][1,4]oxazin-8-il]-[3-(3-fluoro-1H-pirazol-4-il)fenil]metanona; [(3R,9aS)-3-(5-cloro-4-metil-2-piridil)-3,4,6,7,9,9a-hexahidro-1H-pirazino[2,1- c][1,4]oxazin-8-il]-(2-cloro-3-metoxi-fenil)metanona; entre otros. Estos compuestos son inhibidores de monoacilglicerol lipasa (MAGL) destinados al tratamiento o la profilaxis de neuroinflamacion, enfermedades neurodegenerativas, dolor, cancer, trastornos mentales, esclerosis multiple, enfermedad de Alzheimer, enfermedad de Parkinson, esclerosis lateral amiotrofica, traumatismo craneoencefalico, neurotoxicidad, apoplejia, epilepsia, ansiedad, jaqueca y/o depresion.
PE2021002265A 2019-07-09 2020-07-07 Nuevos compuestos heterociclicos PE20220515A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP19185088 2019-07-09
PCT/EP2020/069074 WO2021005034A1 (en) 2019-07-09 2020-07-07 New heterocyclic compounds

Publications (1)

Publication Number Publication Date
PE20220515A1 true PE20220515A1 (es) 2022-04-07

Family

ID=67220669

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2021002265A PE20220515A1 (es) 2019-07-09 2020-07-07 Nuevos compuestos heterociclicos

Country Status (18)

Country Link
US (1) US20220242876A1 (es)
EP (1) EP3997096A1 (es)
JP (1) JP2022539604A (es)
KR (1) KR20220034104A (es)
CN (1) CN114096545A (es)
AR (1) AR119376A1 (es)
AU (1) AU2020311584A1 (es)
BR (1) BR112021026899A2 (es)
CA (1) CA3145338A1 (es)
CL (1) CL2022000019A1 (es)
CO (1) CO2022000186A2 (es)
CR (1) CR20220004A (es)
IL (1) IL288987A (es)
MX (1) MX2022000243A (es)
PE (1) PE20220515A1 (es)
TW (1) TW202116781A (es)
WO (1) WO2021005034A1 (es)
ZA (1) ZA202110352B (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201938164A (zh) 2018-01-08 2019-10-01 瑞士商赫孚孟拉羅股份公司 新穎雜環化合物
WO2020035424A1 (en) 2018-08-13 2020-02-20 F. Hoffmann-La Roche Ag New heterocyclic compounds as monoacylglycerol lipase inhibitors
KR20220062515A (ko) 2019-09-12 2022-05-17 에프. 호프만-라 로슈 아게 Magl 억제제로서 4,4a,5,7,8,8a-헥사피리도[4,3-b][1,4]옥사진-3-온 화합물
CR20230115A (es) 2020-09-03 2023-04-11 Hoffmann La Roche Compuestos heterocíclicos

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2014110401A (ru) * 2011-08-19 2015-09-27 Мерк Шарп И Доум Корп. Ингибиторы внешнего медуллярного калиевого канала почек
EP2934533B1 (en) 2012-12-19 2017-11-15 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
US10323038B2 (en) * 2015-11-20 2019-06-18 Abide Therapeutics, Inc. Pyrazole compounds and methods of making and using same
CN110198944A (zh) * 2017-01-23 2019-09-03 辉瑞大药厂 作为单酰基甘油脂肪酶抑制剂的杂环螺环化合物
JOP20190267A1 (ar) * 2017-05-23 2019-11-18 Lundbeck La Jolla Research Center Inc مثبطات بيرازول magl

Also Published As

Publication number Publication date
US20220242876A1 (en) 2022-08-04
KR20220034104A (ko) 2022-03-17
CO2022000186A2 (es) 2022-01-17
CR20220004A (es) 2022-01-31
CN114096545A (zh) 2022-02-25
AR119376A1 (es) 2021-12-15
WO2021005034A1 (en) 2021-01-14
IL288987A (en) 2022-02-01
CA3145338A1 (en) 2021-01-14
AU2020311584A1 (en) 2022-01-20
CL2022000019A1 (es) 2022-10-21
MX2022000243A (es) 2022-02-03
BR112021026899A2 (pt) 2022-05-10
JP2022539604A (ja) 2022-09-12
TW202116781A (zh) 2021-05-01
ZA202110352B (en) 2022-08-31
EP3997096A1 (en) 2022-05-18

Similar Documents

Publication Publication Date Title
PE20220515A1 (es) Nuevos compuestos heterociclicos
PE20220514A1 (es) Inhibidores de monoacilglicerol lipasa (magl) heterociclicos
PE20211380A1 (es) Nuevos compuestos heterociclicos como inhibidores de monoacilglicerol lipasa
JOP20220247A1 (ar) مثبطات كرومينون تفارغية لفوسفوينوسيتيد 3 كيناز (pi3k) لعلاج أمراض مرتبطة بتعديل p13k
PH12015502323A1 (en) Enantiomers of spiro-oxindole compounds and their uses as therapeutic agents
JO3032B1 (ar) مركبات سبيرو – اوكسندول وإستعمالاتها كعوامل علاجية.
EA200702200A1 (ru) Дигидротиенопиримидины для лечения воспалительных заболеваний
MY167423A (en) Quinoline carboxamide and quinoline carbonitrile derivatives as mglur2-negative allosteric modulators,compositions,and their use
NI201100100A (es) Moduladores de aril metil benzoquinazolinona alostéricos positivos del receptor m1.
RU2009103307A (ru) ПРОИЗВОДНЫЕ ИМИДАЗО[1, 2-a]ПИРИДИН-2-КАРБОКСАМИДОВ, ИХ ПОЛУЧЕНИЕ И ПРИМЕНЕНИЕ В ТЕРАПИИ
AR048789A1 (es) Derivados de oxazol y sus composiciones como moduladores de receptor activado de proliferador de peroxisoma (ppar)
EA200700909A1 (ru) Азаиндолкарбоксамиды
AR087915A1 (es) N-(3-(2-amino-6,6-difluor-4,4a,5,6,7,7a-hexahidro-ciclopenta-[e][1,3]oxazin-4-il)-fenil)-amidas como inhibidores de la bace1
PH12021550381A1 (en) Heteroaryl-substituted sulfonamide compounds and their use as therapeutic agents
JP2009533393A5 (es)
MX2022015703A (es) Compuestos para el tratamiento de enfermedades y trastornos asociados a braf.
JP2019535825A5 (es)
PE20030718A1 (es) Lactamas como antagonistas de taquiquininas
EA202190586A1 (ru) N-замещенные диоксоциклобутениламино-3-гидроксипиколинамиды, приемлемые в качестве ингибиторов ccr6
RU2015112914A (ru) Бензимидазолы в качестве активных агентов для центральной нервной системы
PH12019500597A1 (en) CHROMANE, ISOCHROMANE AND DIHYDROISOBENZOFURAN DERIVATIVES AS mGluR2-NEGATIVE ALLOSTERIC MODULATORS, COMPOSITIONS, AND THEIR USE
MA38012B1 (fr) Dérivés d'éthynyle comme modulateurs de l'activité des récepteurs mglur5
EA202092719A1 (ru) Бензолсульфонамидные соединения и их применение в качестве терапевтических средств
SA520420382B1 (ar) مُعدِّلات تفارغية موجبة تجاه مستقبل دوبامين 1
PL1648904T3 (pl) Związki N-sulfonyloheterocyklopirolioalkiloaminowe jako ligandy 5-hydroksytryptaminy-6